A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia

Millennium Pharmaceuticals, Inc. (Takeda)0 个研究点目标入组 117 人开始时间: 2015年12月21日最近更新: 2022年1月17日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 117

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female patients 18 years or older.
•2. Morphologically confirmed diagnosis of MDS, nonproliferative CMML (ie, with WBC <20,000/µL), or low-blast AML based on 1 of the following:
•French-American-British (FAB) Classifications:
•- Refractory anemia with excess blasts (RAEB – defined as having 5% to 20%
•myeloblasts in the bone marrow).
•- CMML with 10% to 19% myeloblasts in the bone marrow and/or 5% to 19%
•blasts in the blood.
•World Health Organization (WHO) Classifications:
•- Refractory anemia with excess blasts-1 (RAEB-1 – defined as having 5% to 9%
•myeloblasts in the bone marrow).
•- Refractory anemia with excess blasts-2 (RAEB-2 – defined as having 10% to
•19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood).
•- Chronic Myelomonocytic Leukemia-2 (CMML-2 – defined as having 10% to
•19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood).
•- Chronic Myelomonocytic Leukemia-1 (Although CMML-1 is defined as having
•<10% myeloblasts in the bone marrow and/or <5% blasts in the blood, these
•patients may enroll only if bone marrow blasts =5%).
•- WHO-defined AML with 20% to 30% myeloblasts in the bone marrow (defined in this protocol as Low-Blast AML”) and < 30% myeloblasts in peripheral blood who are considered by investigator to be appropriate for azacitidine-based therapy.
•3. For MDS and CMML patients, prognostic Risk Category, based on the Revised International Prognostic Scoring System (IPSS-R):
•- Very high (>6 points),
•- High (>4.5 - 6 points), or
•- Intermediate (>3 – 4.5 points): a patient determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of =5% bone marrow myeloblasts.
•Patients with indeterminate cytogenetics findings at Screening should be
•assigned a cytogenetics prognostic variable of 2 points (ie, intermediate)
•for determining overall Prognostic Risk Category/Score
•4. ECOG performance status of 0 to 2
•5. Clinical laboratory values within the following parameters (repeat
•within 3 days before the first dose of study drug if laboratory values
•used for randomization were obtained more than 3 days before the first dose of study drug):
•- Albumin >2.7 g/dL.
•- Total bilirubin syndrome. Patients with Gilbert’s syndrome may enroll if direct bilirubin = 1.5 x
•ULN of the direct bilirubin.
•- ALT and AST <2.5 × ULN.
•- Creatinine clearance >50 mL/min
•- Hemoglobin >8 g/dL. Patients may be transfused to achieve this value. Elevated indirect bilirubin due to post-transfusion hemolysis is allowed.
•6. For CMML patients: WBC count <20,000/µL before administration of the first dose of study drug on Cycle 1 Day 1; patients must have been off hydroxyurea for at least 1 week prior to WBC count assessment.
•7. Ability to undergo the study-required bone marrow sample collection procedures.
•8. Suitable venous access for the study-required blood sampling (ie, including PK and biomarker sampling).
•9. - Are postmenopausal for at least 1 year before the Screening visit, or
•- Are surgically sterile, or
•- If they are of childbearing potential, agree to practice 1 highly effective
•and 1 additional effective (barrier) method of contraception, at
•the same time, from the time of signing the informed consent through 4
•after the last dose of study drug, or
•- Agree to practice true abstinence, when this is in line with the
•preferred and usual lifestyle

排除标准

•1. Previous treatment with decitabine or azacitidine or other
•hypomethylating agent.
•2. Acute promyelocytic leukemia as diagnosed by morphologic
•examination of bone marrow, by fluorescent in situ hybridization or
•cytogenetics of peripheral blood or bone marrow, or by other accepted
•3. Eligible for allogenic stem cell transplantation.
•4. Patients with MDS, CMML, or low-blast AML, whose only site of disease
•extramedullary, eg, the skin.
•5. Any serious medical or psychiatric illness that could, in the
•investigator's opinion, potentially interfere with the completion of study
•procedures or could limit patient expected survival to less than 6
•6. Treatment with any anti-leukemic/anti-MDS therapies (eg,
•lenalidomide, cytarabine, anthracyclines, purine analogs) or with any
•investigational products within 14 days before the first dose of any study
•7. Known hypersensitivity to mannitol.
•8. Active uncontrolled infection or severe infectious disease, such as
•severe pneumonia, meningitis, or septicemia. 9. Major surgery within 14 days before first dose or a scheduled surgery
•during study period; insertion of a venous access device (eg, catheter,
•port) is not considered major surgery.
•10. Diagnosed or treated for another malignancy within 2 years before
•randomization or previously diagnosed with another malignancy and
•have any evidence of residual disease. Patients with nonmelanoma skin
•cancer or carcinoma in situ of any type are not excluded if they have
•undergone resection.
•11. Life-threatening illness unrelated to cancer.
•12. Prothrombin time (PT) or aPTT > 1.5 ULN or active uncontrolled
•coagulopathy or bleeding disorder.
•13. Known human immunodeficiency virus (HIV) seropositive.
•14. Known hepatitis B surface antigen seropositive, or known or
•suspected active hepatitis C infection. Note: Patients who have isolated
•positive hepatitis B core antibody (ie, in the setting of negative hepatitis
•B surface antigen and negative hepatitis B surface antibody) must have
•an undetectable hepatitis B viral load.
•15. Known hepatic cirrhosis or severe pre-existing hepatic impairment. 16. Known cardiopulmonary disease defined as unstable angina,
•clinically significant arrhythmia, congestive heart failure (New York
•Heart Association [NYHA] Class III or IV; see Section 15.3), and/or
•myocardial infarction within 6 months prior to first dose, or severe
•pulmonary hypertension. As an example, well-controlled atrial
•fibrillation would not be an exclusion whereas uncontrolled atrial
•fibrillation would be an exclusion.
•17. Treatment with strong CYP3A inhibitors or inducers within 14 days
•before the first dose of pevonedistat.
•18. Systemic antineoplastic therapy or radiotherapy for other malignant
•conditions within
•12 months before the first dose of any study drug, except for
•hydroxyurea.
•19. Female patients who are lactating and breastfeeding or have a
•positive serum pregnancy test during the Screening period or a positive
•urine pregnancy test on Day 1 before first dose of study drug.
•20. Female patients who intend to donate eggs (ova) during the course
另有 3 项未显示

研究者

发起方

Millennium Pharmaceuticals, Inc. (Takeda)

相似试验

进行中（未招募）

1 期

A Clinical Study to Compare the Effectiveness and Safety of Azacitidine Versus Pevonedistate Plus Azacitidine in Adults with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous LeukemiaHigher-risk myelodysplastic syndromes (MDS), Chronic myelomonocytic leukemia (CMML), Low-blast acute myelogenous leukemia (AML)MedDRA version: 20.0Level: LLTClassification code 10054350Term: Chronic myelomonocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10024348Term: Leukemia myelogenousSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10024330Term: Leukemia acuteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 20.0Level: PTClassification code 10067387Term: Myelodysplastic syndrome transformationSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10009018Term: Chronic myelomonocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-000221-37-DEMillennium Pharmaceuticals, Inc. (Takeda)117

进行中（未招募）

不适用

EUCTR2015-000221-37-ESMillennium Pharmaceuticals, Inc. (Takeda)117

已完成

2 期

A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia10024324Leukemiacancer

NL-OMON45865Millennium Pharmaceuticals, Inc. (Takeda)6

进行中（未招募）

1 期

A Clinical Study to Compare the Effectiveness and Safety of Azacitidine Versus Pevonedistate Plus Azacitidine in Adults with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous LeukemiaHigher-risk myelodysplastic syndromes (MDS), Chronic myelomonocytic leukemia (CMML), Low-blast acute myelogenous leukemia (AML)MedDRA version: 19.0Level: LLTClassification code 10054350Term: Chronic myelomonocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10024348Term: Leukemia myelogenousSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10024330Term: Leukemia acuteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 19.0Level: PTClassification code 10067387Term: Myelodysplastic syndrome transformationSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10009018Term: Chronic myelomonocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-000221-37-FRMillennium Pharmaceuticals, Inc. (Takeda)117

进行中（未招募）

1 期

EUCTR2015-000221-37-BGMillennium Pharmaceuticals, Inc. (Takeda)120